Biosensors for circulating tumor cells (CTCs)-biomarker detection in lung and prostate cancer: Trends and prospects

• Published in: Biosensors & bioelectronics 2022-02, Vol.197, p.113770-113770, Article 113770
• Main Authors: Hussain, Syed Harris, Huertas, Cesar S., Mitchell, Arnan, Deman, Anne-Laure, Laurenceau, Emmanuelle
• Format: Article
• Language: English
• Subjects: Bioengineering; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Biosensors; Cancer; Circulating tumor cells; Humans; Life Sciences; Lung; Lung cancer; Male; Neoplastic Cells, Circulating; Prostate cancer; Prostatic Neoplasms - diagnosis
• ISSN: 0956-5663; 1873-4235
• DOI: 10.1016/j.bios.2021.113770

Cancer is one of the leading cause of death worldwide. Lung cancer (LCa) and prostate cancer (PCa) are the two most common ones particularly among men with about 20% of aggressive metastatic form leading to shorter overall survival. In recent years, circulating tumor cells (CTCs) have been investigated extensively for their role in metastatic progression and their involvement in reduced overall survival and treatment responses. Analysis of these cells and their associated biomarkers as “liquid biopsy” can provide valuable real-time information regarding the disease state and can be a potential avenue for early-stage detection and possible selection of personalized treatments. This review focuses on the role of CTCs and their associated biomarkers in lung and prostate cancer, as well as the shortcomings of conventional methods for their isolation and analysis. To overcome these drawbacks, biosensors are an elegant alternative because they are capable of providing valuable multiplexed information in real-time and analyzing biomarkers at lower concentrations. A comparative analysis of different transducing elements specific for the analysis of cancer cell and cancer biomarkers have been compiled in this review. •Circulating tumor cells (CTCs) and their associated biomarkers are relevant tools for cancer diagnosis.•Liquid biopsy provides valuable real-time information for cancer follow-up and possible selection of personalized treatments.•Biosensors provides valuable multiplexed information in real-time and analyzing biomarkers at lower concentrations.•Development of label-free nano-biosensors for analyzing CTC and their biomarkers allows microfluidic integration.